Ipamorelin 5mg

Certificate of Analysis (COA): See Images

Ipamorelin is a synthetic pentapeptide classified as a selective growth hormone secretagogue (GHS). It belongs to the group of ghrelin mimetics, designed to stimulate the release of growth hormone (GH) without significantly affecting other hormones such as cortisol or prolactin. Because of this selective profile, Ipamorelin is a popular focus in preclinical research exploring growth hormone regulation, metabolism, and recovery pathways.

Area of Interest

Ipamorelin is widely studied in laboratory and animal models for the following areas of research:

• Growth Hormone Release: Demonstrated ability to increase GH secretion through ghrelin receptor (GHSR-1a) activation.
• Selective Action: Unlike earlier secretagogues (e.g., GHRP-6), Ipamorelin shows minimal effects on prolactin, ACTH, or cortisol, making it highly selective.
• Metabolic Research: Investigated for potential roles in body composition, fat metabolism, and energy balance studies.
• Regenerative & Musculoskeletal Models: Preclinical evidence suggests interest in recovery, repair, and musculoskeletal adaptation pathways.

Its unique selectivity makes Ipamorelin valuable for studying the growth hormone axis without the confounding influence of stress hormones.

Technical Information

• Chemical Name: Ipamorelin
• Synonyms: Ipamorelin Acetate
• Molecular Formula: C₃₈H₄₉N₉O₅
• Molecular Weight: 711.86 g/mol
• Sequence (Amino Acid): Aib-His-D-2-Nal-D-Phe-Lys-NH₂
• CAS Number: 170851-70-4
• Peptide Classification: Growth hormone secretagogue (GHS) / Ghrelin mimetic

Storage Guidelines

• Lyophilized powder may be kept at room temperature for a few weeks.
• For long-term storage, maintain at −20°C or below.
• Once reconstituted, store at 2–8 °C. Effective use depends on the solution used.

Solubility

Soluble in sterile water, acetic acid, or suitable aqueous buffers.

References

• Jönsson, A. C., et al. (2001). “Ipamorelin, a new growth-hormone-releasing peptide, selectively stimulates GH release in healthy men.” Journal of Clinical Endocrinology & Metabolism, 86(8), 3877–3883. https://doi.org/10.1210/jcem.86.8.7743
• Raun, K., et al. (1998). “Ipamorelin, the first selective growth hormone secretagogue.” European Journal of Endocrinology, 139(5), 552–561. https://doi.org/10.1530/eje.0.1390552